#Jazz Pharmaceuticals #HER2-targeted therapy #Pipeline Products

Jazz Pharmaceuticals Stands Out with Remarkable 2025 Financial Outcomes

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released its financial results for 2025, showcasing a record total revenue of $4.3 billion, reflecting a 5% increase from the previous year. The company also reported an outstanding performance in the fourth quarter, achieving $1.2 billion, representing a remarkable 10% year-over-year growth. This achievement marks the 21st consecutive year of revenue growth for Jazz Pharmaceuticals, demonstrating the company's resilience and operational excellence.

Key Revenue Highlights

In 2025, Jazz Pharmaceuticals experienced an upward trajectory in its product sales. Notable contributions came from:

• - Xywav®, which generated $1.7 billion in revenue and marked a 12% increase compared to the previous year, solidifying its leadership in rare sleep disorders.
• - Epidiolex®, recording revenues of $1.1 billion and a 9% year-over-year growth, highlighting its pivotal role in the epilepsy market.
• - The successful launch of Modeyso™, which brought in $37 million in revenue during its first full quarter, underscoring its rapid adoption.

Future Growth Projections

Looking forward to 2026, Jazz Pharmaceuticals expects total revenues to be between $4.25 billion and $4.50 billion. This optimistic forecast is underpinned by the anticipated launch of zanidatamab for treating HER2-positive gastroesophageal adenocarcinoma (GEA) and continued growth from existing specialties including epilepsy and oncology franchises. President and CEO Renee Gala stated, “This performance provides us with strong momentum heading into 2026 as we prepare for potential product launches.